Research and analysis

Review of the use of haloperidol in elderly patients with acute delirium

Public Assessment Report on our review of the risks of using haloperidol for the acute treatment of delirium in elderly patients.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 10 December 2021

Documents

Review of the use of haloperidol in elderly patients with acute delirium

HTML

Review of the use of haloperidol in elderly patients with acute delirium

PDF, 380 KB, 33 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The aim of our Safety Public Assessment Reports is to discuss evidence-based assessments of safety issues for a particular drug or drug class.

The report provides a summary of the review of available safety data for the use of haloperidol in the treatment of acute delirium in elderly patients.

We remind healthcare professionals that special caution is needed when using haloperidol for the acute treatment of delirium in elderly people. This is due to the increased risk of adverse effects in this patient group.

Published 10 December 2021